Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00725764 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

A Phase 2 study of Neoplasms, Head and Neck, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
14
Enrollment target
11
Study locations

NCT00725764 is a Phase 2 study of Neoplasms, Head and Neck that has completed, run by GlaxoSmithKline. The registered enrollment target is 14 participants, below the 407-participant average among 4 other Neoplasms, Head and Neck trials with a reported enrollment target (97% lower). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00725764, a Phase 2 study of Neoplasms, Head and Neck, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
14 participants
Enrollment target
11
Study locations

Study Summary

This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN). GSK1363089 is a new chemical entity that inhibits multiple receptor tyrosine kinases (RTKs) with growth-promoting and angiogenic properties. The primary targets of GSK1363089 are the HGF and vascular endothelial growth factor (VEGF) RTK families (eg, MET, VEGFR2/kinase insert domain receptor \[KDR\]). Since MET overexpression has been associated with poorer prognosis and MET tyrosine kinase mutations have been reported in SCCHN, inhibition of MET receptor and VEGFR2/KDR activation by agents such as GSK1363089 may be of therapeutic benefit in this patient population.

Conditions Studied

Neoplasms, Head and Neck

Interventions

  • DRUG GSK1363089 (foretinib)

Study Locations (11)

Texas

  • GSK Investigational Site - Houston
  • GSK Investigational Site - San Antonio

Georgia

  • GSK Investigational Site - Atlanta

Illinois

  • GSK Investigational Site - Chicago

Indiana

  • GSK Investigational Site - Indianapolis

Minnesota

  • GSK Investigational Site - Minneapolis

Missouri

  • GSK Investigational Site - St Louis

New Hampshire

  • GSK Investigational Site - Lebanon

South Carolina

  • GSK Investigational Site - Charleston

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2007-08-27
Est. Completion 2009-05-02
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00725764

The ClinicalTrials.gov registry entry for NCT00725764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 407-participant average among 4 other Neoplasms, Head and Neck trials with a reported enrollment target (97% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms, Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which GSK1363089 (foretinib) is the first listed.

NCT00725764 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Texas, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT00725764 about?

NCT00725764 is a clinical study titled "Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck". This study is being conducted to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in adult subjects with squamous cell carcinoma of the head and neck (SCCHN). GSK1363089 is a new chemical entity that inhibits multiple receptor tyrosine kinases (RTKs) with ...

What is the current status of trial NCT00725764?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2007-08-27. Estimated completion is 2009-05-02.

What conditions does trial NCT00725764 study?

This clinical trial studies the following conditions: Neoplasms, Head and Neck.

What interventions are being tested in trial NCT00725764?

The interventions under investigation include: GSK1363089 (foretinib) (DRUG).

Who is sponsoring clinical trial NCT00725764?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00725764 being conducted?

This trial has 11 study locations across Georgia, Illinois, Indiana, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms, Head and Neck

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms, Head and Neck

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.